Search

Your search keyword '"Imamura, Chiyo K."' showing total 7 results
Start Over Author "Imamura, Chiyo K." Publisher wiley
7 results on '"Imamura, Chiyo K."'

1. Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application

Author

Takeuchi, Masashi, primary, Imamura, Chiyo K., additional, Booka, Eisuke, additional, Takeuchi, Hiroya, additional, Mizukami, Takuro, additional, Kawakami, Takeshi, additional, Funakoshi, Taro, additional, Wakuda, Kazushige, additional, Aoki, Yu, additional, Hamamoto, Yasuo, additional, Kitago, Minoru, additional, Kawakubo, Hirofumi, additional, Boku, Narikazu, additional, Tanigawara, Yusuke, additional, and Kitagawa, Yuko, additional

Published
2021
Full Text
View/download PDF

2. A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

Author

Matsumoto, Koji, primary, Takahashi, Masato, additional, Sato, Kazuhiko, additional, Osaki, Akihiko, additional, Takano, Toshimi, additional, Naito, Yoichi, additional, Matsuura, Kazuo, additional, Aogi, Kenjiro, additional, Fujiwara, Kimiko, additional, Tamura, Kenji, additional, Baba, Motoi, additional, Tokunaga, Shinya, additional, Hirano, Gen, additional, Imoto, Shigeru, additional, Miyazaki, Chieko, additional, Yanagihara, Kazuhiro, additional, Imamura, Chiyo K., additional, Chiba, Yasutaka, additional, and Saeki, Toshiaki, additional

Published
2020
Full Text
View/download PDF

4. The effects of advanced age and serum α1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients

Author

Kenmotsu, Hirotsugu, primary, Imamura, Chiyo K., additional, Ono, Akira, additional, Omori, Shota, additional, Nakashima, Kazuhisa, additional, Wakuda, Kazushige, additional, Taira, Tetsuhiko, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Takahashi, Toshiaki, additional, and Tanigawara, Yusuke, additional

Published
2017
Full Text
View/download PDF

5. Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer

Author

Otsubo, Kohei, primary, Nosaki, Kaname, additional, Imamura, Chiyo K., additional, Ogata, Hiroaki, additional, Fujita, Akitaka, additional, Sakata, Shinya, additional, Hirai, Fumihiko, additional, Toyokawa, Gouji, additional, Iwama, Eiji, additional, Harada, Taishi, additional, Seto, Takashi, additional, Takenoyama, Mitsuhiro, additional, Ozeki, Takeshi, additional, Mushiroda, Taisei, additional, Inada, Mieko, additional, Kishimoto, Junji, additional, Tsuchihashi, Kenji, additional, Suina, Kentaro, additional, Nagano, Osamu, additional, Saya, Hideyuki, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2017
Full Text
View/download PDF

7. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.

Author

Imamura CK, Furihata K, Okamoto S, and Tanigawara Y

Subjects
Adult, Antifungal Agents pharmacokinetics, Area Under Curve, Cross-Over Studies, Drug Therapy, Combination methods, Genotype, Healthy Volunteers, Humans, Male, Young Adult, Cytochrome P-450 CYP2C19 genetics, Polymorphism, Genetic genetics, Tacrolimus pharmacokinetics, Voriconazole pharmacokinetics
Abstract

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24 ) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P < .05 and P < .01, respectively). Consequently, AUC0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P < .05). These results demonstrate that CYP2C19 genotypes influenced the exposure of tacrolimus when coadministered with voriconazole, although tacrolimus is mainly metabolized by CYP3A., (© 2015, The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results